Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

General Assembly, Prevention, Host Related General: Proceedings of International Consensus on Orthopedic Infections.

Zainul-Abidin S, Amanatullah DF, Anderson MB, Austin M, Barretto JM, Battenberg A, Bedard NA, Bell K, Blevins K, Callaghan JJ, Cao L, Certain L, Chang Y, Chen JP, Cizmic Z, Coward J, DeMik DE, Diaz-Borjon E, Enayatollahi MA, Feng JE, Fernando N, Gililland JM, Goodman S, Goodman S, Greenky M, Hwang K, Iorio R, Karas V, Khan R, Kheir M, Klement MR, Kunutsor SK, Limas R, Morales Maldonado RA, Manrique J, Matar WY, Mokete L, Nung N, Pelt CE, Pietrzak JRT, Premkumar A, Rondon A, Sanchez M, Novaes de Santana C, Sheth N, Singh J, Springer BD, Tay KS, Varin D, Wellman S, Wu L, Xu C, Yates AJ.

J Arthroplasty. 2019 Feb;34(2S):S13-S35. doi: 10.1016/j.arth.2018.09.050. Epub 2018 Oct 22. No abstract available.

PMID:
30360983
2.

L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.

Nguyen THM, Carreira PE, Sanchez-Luque FJ, Schauer SN, Fagg AC, Richardson SR, Davies CM, Jesuadian JS, Kempen MHC, Troskie RL, James C, Beaven EA, Wallis TP, Coward JIG, Chetty NP, Crandon AJ, Venter DJ, Armes JE, Perrin LC, Hooper JD, Ewing AD, Upton KR, Faulkner GJ.

Cell Rep. 2018 Jun 26;23(13):3730-3740. doi: 10.1016/j.celrep.2018.05.090.

3.

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.

Feng S, Coward J, McCaffrey E, Coucher J, Kalokerinos P, O'Byrne K.

J Thorac Oncol. 2017 Nov;12(11):1626-1635. doi: 10.1016/j.jtho.2017.08.007. Epub 2017 Aug 24. Review.

4.

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.

Makarious D, Horwood K, Coward JIG.

Eur J Cancer. 2017 Sep;82:128-136. doi: 10.1016/j.ejca.2017.05.041. Epub 2017 Jun 27. Review.

PMID:
28666240
5.

Penicillin Dried Blood Spot Assay for Use in Patients Receiving Intramuscular Benzathine Penicillin G and Other Penicillin Preparations To Prevent Rheumatic Fever.

Page-Sharp M, Coward J, Moore BR, Salman S, Marshall L, Davis TME, Batty KT, Manning L.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00252-17. doi: 10.1128/AAC.00252-17. Print 2017 Aug.

6.

Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.

Porceddu SV, Milne R, Brown E, Bernard A, Rahbari R, Cartmill B, Foote M, McGrath M, Coward J, Panizza B.

Oral Oncol. 2017 Mar;66:81-86. doi: 10.1016/j.oraloncology.2017.01.002. Epub 2017 Jan 21.

PMID:
28249652
7.

Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.

Ho GY, Woodward N, Coward JI.

Crit Rev Oncol Hematol. 2016 Jun;102:37-46. doi: 10.1016/j.critrevonc.2016.03.014. Epub 2016 Mar 24. Review.

PMID:
27105947
8.

The Clinical Dilemma of Incidental Findings on the Low-Resolution CT Images from SPECT/CT MPI Studies.

Coward J, Nightingale J, Hogg P.

J Nucl Med Technol. 2016 Sep;44(3):167-72. doi: 10.2967/jnmt.116.174557. Epub 2016 Apr 21. Review.

9.

Mucinous ovarian cancer: A therapeutic review.

Xu W, Rush J, Rickett K, Coward JI.

Crit Rev Oncol Hematol. 2016 Jun;102:26-36. doi: 10.1016/j.critrevonc.2016.03.015. Epub 2016 Mar 19. Review.

PMID:
27083591
10.

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.

Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, Roche DK, Kennedy C, Chetty NP, Crandon AJ, Flatley C, Oliveira NB, Shannon CM, deFazio A, Tinker AV, Gilks CB, Gabrielli B, Brennan DJ, Coward JI, Armes JE, Perrin LC, Hooper JD.

Br J Cancer. 2016 Feb 16;114(4):417-26. doi: 10.1038/bjc.2015.471. Epub 2016 Feb 4.

11.

Multicentre analysis of incidental findings on low-resolution CT attenuation correction images: an extended study.

Coward J, Lawson R, Kane T, Elias M, Howes A, Birchall J, Hogg P.

Br J Radiol. 2015;88(1056):20150555. doi: 10.1259/bjr.20150555. Epub 2015 Oct 23.

12.

Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.

He Y, Wu AC, Harrington BS, Davies CM, Wallace SJ, Adams MN, Palmer JS, Roche DK, Hollier BG, Westbrook TF, Hamidi H, Konecny GE, Winterhoff B, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Tinker AV, Gilks CB, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD.

Oncogene. 2016 Jan 28;35(4):468-78. doi: 10.1038/onc.2015.101. Epub 2015 Apr 20.

13.

The role of interleukin-6 in malignant mesothelioma.

Abdul Rahim SN, Ho GY, Coward JI.

Transl Lung Cancer Res. 2015 Feb;4(1):55-66. doi: 10.3978/j.issn.2218-6751.2014.07.01. Review.

14.

New perspectives on targeted therapy in ovarian cancer.

Coward JI, Middleton K, Murphy F.

Int J Womens Health. 2015 Feb 4;7:189-203. doi: 10.2147/IJWH.S52379. eCollection 2015. Review.

15.

The tolerability of sunitinib in elderly patients with metastatic renal cancer.

Michael A, Coward J, Brown A, Barber N, Pandha H.

Clin Oncol (R Coll Radiol). 2015 Jun;27(6):371-2. doi: 10.1016/j.clon.2015.01.012. Epub 2015 Feb 3. No abstract available.

PMID:
25659887
16.

Lesion detection performance: comparative analysis of low-dose CT data of the chest on two hybrid imaging systems.

Jessop M, Thompson JD, Coward J, Sanderud A, Jorge J, de Groot M, Lança L, Hogg P.

J Nucl Med Technol. 2015 Mar;43(1):47-52. doi: 10.2967/jnmt.114.147447. Epub 2015 Jan 22.

17.

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

Minchom AR, Saksornchai K, Bhosle J, Gunapala R, Puglisi M, Lu SK, Nimako K, Coward J, Yu KC, Bordi P, Popat S, O'Brien ME.

BMJ Open Respir Res. 2014 Dec 11;1(1):e000061. doi: 10.1136/bmjresp-2014-000061. eCollection 2014.

18.

Multi-centre analysis of incidental findings on low-resolution CT attenuation correction images.

Coward J, Lawson R, Kane T, Elias M, Howes A, Birchall J, Hogg P.

Br J Radiol. 2014 Oct;87(1042):20130701. doi: 10.1259/bjr.20130701. Epub 2014 Aug 19.

19.

Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer.

Coward J, Harding A.

Front Oncol. 2014 May 26;4:123. doi: 10.3389/fonc.2014.00123. eCollection 2014. Review.

20.

EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface.

Adams MN, Harrington BS, He Y, Davies CM, Wallace SJ, Chetty NP, Crandon AJ, Oliveira NB, Shannon CM, Coward JI, Lumley JW, Perrin LC, Armes JE, Hooper JD.

Oncogene. 2015 Mar 12;34(11):1375-83. doi: 10.1038/onc.2014.88. Epub 2014 Mar 31.

PMID:
24681947
21.

Serum HE4 as a prognostic marker in endometrial cancer--a population based study.

Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, Quinn MA, Janda M, Leung Y, Freemantle M; ANECS Group, Webb PM, Spurdle AB, Obermair A.

Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.

PMID:
24211402
22.

Chemotherapy advances in small-cell lung cancer.

Chan BA, Coward JI.

J Thorac Dis. 2013 Oct;5 Suppl 5:S565-78. doi: 10.3978/j.issn.2072-1439.2013.07.43. Review.

23.

A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology.

De Ieso PB, Coward JI, Letsa I, Schick U, Nandhabalan M, Frentzas S, Gore ME.

Br J Cancer. 2013 Oct 29;109(9):2295-300. doi: 10.1038/bjc.2013.586. Epub 2013 Oct 1.

24.

Interleukin-6: an angiogenic target in solid tumours.

Middleton K, Jones J, Lwin Z, Coward JI.

Crit Rev Oncol Hematol. 2014 Jan;89(1):129-39. doi: 10.1016/j.critrevonc.2013.08.004. Epub 2013 Aug 28. Review.

PMID:
24029605
25.

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.

Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT; Australian Prostate Cancer BioResource, Craik DJ, Parton RG, Russell PJ, Hill MM.

Oncogene. 2014 Jul 3;33(27):3561-70. doi: 10.1038/onc.2013.315. Epub 2013 Aug 12.

PMID:
23934189
26.

Characteristics of infections associated with external ventricular drains of cerebrospinal fluid.

Walti LN, Conen A, Coward J, Jost GF, Trampuz A.

J Infect. 2013 May;66(5):424-31. doi: 10.1016/j.jinf.2012.12.010. Epub 2013 Jan 9.

PMID:
23313468
27.

The role of interleukin-6 in gynaecological malignancies.

Coward JI, Kulbe H.

Cytokine Growth Factor Rev. 2012 Dec;23(6):333-42. doi: 10.1016/j.cytogfr.2012.08.005. Epub 2012 Sep 30. Review.

PMID:
23031497
28.

Paraneoplastic thrombocytosis in ovarian cancer.

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 10.1056/NEJMoa1110352. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Lamkin, Donald [added].

29.

Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report.

Coward JI, Ding NL, Feakins R, Kocher H, Popat S, Szlosarek PW.

Med Oncol. 2012 Dec;29(4):2623-5. doi: 10.1007/s12032-011-0150-3. Epub 2011 Dec 28.

PMID:
22203382
30.

True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer.

Coward JI, Nathavitharana R, Popat S.

Lung Cancer. 2012 Jan;75(1):133-5. doi: 10.1016/j.lungcan.2011.11.001. Epub 2011 Nov 27.

PMID:
22126907
31.

A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.

O'Brien ME, Myerson JS, Coward JI, Puglisi M, Trani L, Wotherspoon A, Sharma B, Cook G, Ashley S, Gunapala R, Chua S, Popat S.

Eur J Cancer. 2012 Jan;48(1):68-74. doi: 10.1016/j.ejca.2011.10.033. Epub 2011 Nov 24.

PMID:
22119198
32.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7.

33.

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.

Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.

34.

FTIR spectroscopy of synthesized racemic nonacosan-10-ol: a model compound for plant epicuticular waxes.

Coward JL.

J Biol Phys. 2010 Sep;36(4):405-25. doi: 10.1007/s10867-010-9192-6. Epub 2010 Aug 5.

35.

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.

36.

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD.

Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22.

37.

Dectin-1 diversifies Aspergillus fumigatus-specific T cell responses by inhibiting T helper type 1 CD4 T cell differentiation.

Rivera A, Hohl TM, Collins N, Leiner I, Gallegos A, Saijo S, Coward JW, Iwakura Y, Pamer EG.

J Exp Med. 2011 Feb 14;208(2):369-81. doi: 10.1084/jem.20100906. Epub 2011 Jan 17.

38.

Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response.

Feinerman O, Jentsch G, Tkach KE, Coward JW, Hathorn MM, Sneddon MW, Emonet T, Smith KA, Altan-Bonnet G.

Mol Syst Biol. 2010 Nov 30;6:437. doi: 10.1038/msb.2010.90.

39.

Perspectives for computer modeling in the study of T cell activation.

Coward J, Germain RN, Altan-Bonnet G.

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a005538. doi: 10.1101/cshperspect.a005538. Epub 2010 May 5. Review.

40.

UDP-(5F)-GlcNAc acts as a slow-binding inhibitor of MshA, a retaining glycosyltransferase.

Frantom PA, Coward JK, Blanchard JS.

J Am Chem Soc. 2010 May 19;132(19):6626-7. doi: 10.1021/ja101231a.

41.

Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition.

Wang P, Wang Q, Yang Y, Coward JK, Nzila A, Sims PF, Hyde JE.

Mol Biochem Parasitol. 2010 Jul;172(1):41-51. doi: 10.1016/j.molbiopara.2010.03.012. Epub 2010 Mar 27.

42.

Developing a ward accreditation scheme to improve infection control practice.

Coward J, Palmer D, Risebury B, Collingwood K.

Nurs Times. 2009 Nov 10-16;105(44):24-6.

PMID:
20092213
43.

Hsp70 expression in monocytes from patients with peripheral arterial disease and healthy controls: monocyte Hsp70 in PAD.

Madden J, Coward JC, Shearman CP, Grimble RF, Calder PC.

Cell Biol Toxicol. 2010 Jun;26(3):215-23. doi: 10.1007/s10565-009-9134-x. Epub 2009 Aug 12.

PMID:
19672680
44.

Inhibition of human folylpolyglutamate synthetase by diastereomeric phosphinic acid mimics of the tetrahedral intermediate.

McGuire JJ, Bartley DM, Tomsho JW, Haile WH, Coward JK.

Arch Biochem Biophys. 2009 Aug 15;488(2):140-5. doi: 10.1016/j.abb.2009.06.017. Epub 2009 Jun 27. Erratum in: Arch Biochem Biophys. 2010 Jan 15;493(2):250.

45.

Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.

Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G, Keen N, Schwartz GK.

Mol Biol Cell. 2009 Apr;20(8):2218-28. doi: 10.1091/mbc.E08-08-0885. Epub 2009 Feb 18.

46.

Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway.

Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC, Wang E, Merrill AH Jr, Schwartz GK.

Autophagy. 2009 Feb;5(2):184-93. Epub 2009 Feb 6.

PMID:
19098447
47.

Synthesis of isopeptide epoxide peptidomimetics.

Majumdar D, Alexander MD, Coward JK.

J Org Chem. 2009 Jan 16;74(2):617-27. doi: 10.1021/jo801907p.

48.

ATP-dependent ligases in trypanothione biosynthesis--kinetics of catalysis and inhibition by phosphinic acid pseudopeptides.

Oza SL, Chen S, Wyllie S, Coward JK, Fairlamb AH.

FEBS J. 2008 Nov;275(21):5408-21. doi: 10.1111/j.1742-4658.2008.06670.x.

49.
50.

Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase.

Tomsho JW, Moran RG, Coward JK.

Biochemistry. 2008 Aug 26;47(34):9040-50. doi: 10.1021/bi800406w. Epub 2008 Aug 2.

Supplemental Content

Loading ...
Support Center